Lynparza Maintenance Reduces Risk of Disease Progression in Advanced Ovarian Cancer Patients, SOLO-2 Trial Shows

Lynparza Maintenance Reduces Risk of Disease Progression in Advanced Ovarian Cancer Patients, SOLO-2 Trial Shows
Women with BRCA-mutated relapsed ovarian cancer whose tumors responded to platinum-based chemotherapy took significantly longer to see their disease progressing when given AstraZeneca’s Lynparza (olaparib) as a maintenance therapy, compared to placebo. In addition to showing a 70 percent reduction in the risk of disease progression, the SOLO-2 Phase 3 trial (NCT01874353) revealed that Lynparza treatment did not reduce patients' quality of life, as reported by patients. The study, "Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial," was published in the journal Lancet Oncology. Lynparza belongs to a group of pharmaceuticals known as PARP inhibitors. It targets an enzyme, called PARP, which plays a role in repairing DNA errors in cells. The drug is particularly effective in cancers with mutations in other DNA-repairing genes, like BRCA 1 and BRCA2, which rely mainly on the PARP enzymes to counteract DNA damage. “Given the few treatment options available for patients with platinum-sensitive, relapsed ovarian cancer, the data for olaparib as maintenance therapy in SOLO2 are notable,” the authors stated. Lynparza was approved this month by the U.S. Food and Drug Administration as a maintenance therapy for relapsed ovarian cancer, following results from two trials: The SOLO-2 Phase 3 trial, and the Study 19 Phase 2 trial (NCT00753545). The SOLO2/ENGOT-Ov21 trial, funded by AstraZeneca, randomized 295 patients in a 2:1 ratio to receive either Lynparza 300 mg tablets twice daily, or placebo. After a median follow-up of roughly 22 months, the time to disease progression or death was 19.1 mont
Subscribe or to access all post and page content.